215 related articles for article (PubMed ID: 18536657)
1. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum.
Shafizadeh N; Ferrell LD; Kakar S
Mod Pathol; 2008 Aug; 21(8):1011-8. PubMed ID: 18536657
[TBL] [Abstract][Full Text] [Related]
2. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
[TBL] [Abstract][Full Text] [Related]
3. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma.
Lagana SM; Salomao M; Bao F; Moreira RK; Lefkowitch JH; Remotti HE
Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):170-6. PubMed ID: 22914605
[TBL] [Abstract][Full Text] [Related]
4. A triple stain of reticulin, glypican-3, and glutamine synthetase: a useful aid in the diagnosis of liver lesions.
Swanson BJ; Yearsley MM; Marsh W; Frankel WL
Arch Pathol Lab Med; 2015 Apr; 139(4):537-42. PubMed ID: 25822763
[TBL] [Abstract][Full Text] [Related]
5. Combined use of heat-shock protein 70 and glutamine synthetase is useful in the distinction of typical hepatocellular adenoma from atypical hepatocellular neoplasms and well-differentiated hepatocellular carcinoma.
Nguyen TB; Roncalli M; Di Tommaso L; Kakar S
Mod Pathol; 2016 Mar; 29(3):283-92. PubMed ID: 26769138
[TBL] [Abstract][Full Text] [Related]
6. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.
Libbrecht L; Severi T; Cassiman D; Vander Borght S; Pirenne J; Nevens F; Verslype C; van Pelt J; Roskams T
Am J Surg Pathol; 2006 Nov; 30(11):1405-11. PubMed ID: 17063081
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 5 Immunohistochemical Markers of Hepatocellular Differentiation for the Diagnosis of Hepatocellular Carcinoma.
Nguyen T; Phillips D; Jain D; Torbenson M; Wu TT; Yeh MM; Kakar S
Arch Pathol Lab Med; 2015 Aug; 139(8):1028-34. PubMed ID: 26230595
[TBL] [Abstract][Full Text] [Related]
8. [Expression and clinicopathologic significance of GPC3 and other antibodies in well-differentiated hepatocellular carcinoma].
DU JL; Wei LX; Wang YL
Zhonghua Bing Li Xue Za Zhi; 2011 Jan; 40(1):11-6. PubMed ID: 21429352
[TBL] [Abstract][Full Text] [Related]
9. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
Nassar A; Cohen C; Siddiqui MT
Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
[TBL] [Abstract][Full Text] [Related]
10. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.
Yamauchi N; Watanabe A; Hishinuma M; Ohashi K; Midorikawa Y; Morishita Y; Niki T; Shibahara J; Mori M; Makuuchi M; Hippo Y; Kodama T; Iwanari H; Aburatani H; Fukayama M
Mod Pathol; 2005 Dec; 18(12):1591-8. PubMed ID: 15920546
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemistry in the Diagnosis of Hepatocellular Carcinoma.
Choi WT; Kakar S
Gastroenterol Clin North Am; 2017 Jun; 46(2):311-325. PubMed ID: 28506367
[TBL] [Abstract][Full Text] [Related]
12. Agrin and CD34 immunohistochemistry for the discrimination of benign versus malignant hepatocellular lesions.
Tátrai P; Somorácz A; Batmunkh E; Schirmacher P; Kiss A; Schaff Z; Nagy P; Kovalszky I
Am J Surg Pathol; 2009 Jun; 33(6):874-85. PubMed ID: 19194276
[TBL] [Abstract][Full Text] [Related]
13. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders.
Zhu ZW; Friess H; Wang L; Abou-Shady M; Zimmermann A; Lander AD; Korc M; Kleeff J; Büchler MW
Gut; 2001 Apr; 48(4):558-64. PubMed ID: 11247902
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression in hepatocellular carcinoma. A clinicopathological analysis with emphasis on diagnostic value.
Wachter DL; Kristiansen G; Soll C; Hellerbrand C; Breuhahn K; Fritzsche F; Agaimy A; Hartmann A; Riener MO
Histopathology; 2012 Jan; 60(2):278-86. PubMed ID: 22211286
[TBL] [Abstract][Full Text] [Related]
15. Roles of Combined Glypican-3 and Glutamine Synthetase in Differential Diagnosis of Hepatocellular Lesions.
Wasfy RE; Shams Eldeen AA
Asian Pac J Cancer Prev; 2015; 16(11):4769-75. PubMed ID: 26107238
[TBL] [Abstract][Full Text] [Related]
16. [Significance of glypican-3 immunohistochemistry in diagnosis of hepatocellular carcinoma].
Yip YC; Wang FH; Vong HT; Zhang M; Wen JM
Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):626-9. PubMed ID: 22177248
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma arising in adenoma: similar immunohistochemical and cytogenetic features in adenoma and hepatocellular carcinoma portions of the tumor.
Kakar S; Grenert JP; Paradis V; Pote N; Jakate S; Ferrell LD
Mod Pathol; 2014 Nov; 27(11):1499-1509. PubMed ID: 24743216
[TBL] [Abstract][Full Text] [Related]
18. Application of Immunohistochemistry in the Pathological Diagnosis of Liver Tumors.
Takahashi Y; Dungubat E; Kusano H; Ganbat D; Tomita Y; Odgerel S; Fukusato T
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071338
[TBL] [Abstract][Full Text] [Related]
19. Claudins and tricellulin in fibrolamellar hepatocellular carcinoma.
Patonai A; Erdélyi-Belle B; Korompay A; Somorácz A; Straub BK; Schirmacher P; Kovalszky I; Lotz G; Kiss A; Schaff Z
Virchows Arch; 2011 Jun; 458(6):679-88. PubMed ID: 21503766
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver.
Ibrahim TR; Abdel-Raouf SM
Pathol Oncol Res; 2015 Apr; 21(2):379-87. PubMed ID: 25108409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
